https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-01 / Immunotherapy 2010 Mar;2(2):185-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-01 / Immunotherapy 2010 Mar;2(2):185-992010-03-01 00:00:002019-02-15 09:21:47New perspectives in cancer virotherapy: bringing the immune system into play
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-04 / Cancer Immunol. Immunother. 2010 Jul;59(7):989-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-04 / Cancer Immunol. Immunother. 2010 Jul;59(7):989-992010-02-04 00:00:002019-02-15 09:21:48The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-25 / Oncogene 2010 Apr;29(15):2205-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-25 / Oncogene 2010 Apr;29(15):2205-162010-01-25 00:00:002019-02-15 09:21:49Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / J. Virol. 2010 Jan;84(1):639-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / J. Virol. 2010 Jan;84(1):639-462010-01-01 00:00:002010-01-01 00:00:00The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-13 / Int. J. Urol. 2010 Jan;17(1):20-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-13 / Int. J. Urol. 2010 Jan;17(1):20-302009-10-13 00:00:002009-10-13 00:00:00Oncolytic virus therapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-06 / Mol. Ther. 2010 Feb;18(2):275-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-06 / Mol. Ther. 2010 Feb;18(2):275-842009-10-06 00:00:002009-10-06 00:00:00Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-222009-09-01 00:00:002021-11-15 17:00:58Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-10 / J. Virol. 2009 Aug;83(16):8108-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-10 / J. Virol. 2009 Aug;83(16):8108-212009-06-10 00:00:002021-11-15 17:01:25Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-822009-04-01 00:00:002021-11-15 17:01:56Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-622009-04-01 00:00:002021-11-15 17:02:15Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
